Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Shuling Guo is the Executive Director of Exploratory Drug Discovery at Ionis Pharmaceuticals. She received her Ph.D. in Molecular Cancer Biology from Duke University and had her postdoctoral training at HHMI/UCLA. At Ionis, Dr. Guo oversees drug discovery efforts in hematological, metabolic, ocular, pulmonary and renal disease areas as well as research efforts in noncoding RNA field. She manages activities from target identification, target validation to the selection of human development candidate. In addition, she is involved in clinical development of antisense therapies. Dr. Guo led the research efforts for transthyretin (familial amyloid polyneuropathy, completed phase 3 clinical trial & under NDA), TMPRSS6 (beta-thalassemia and hereditary hemochromatosis, phase 1 clinical trial), and ENaC (cystic fibrosis, preclinical development).